Related Experiment Video
Updated: Jul 30, 2025
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective,
Bowu Chen1, Yan Xue2, Hua Jing3
1Department of Hepatology, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Insights
Huashibaidu granule (HSBD) effectively treats mild COVID-19 patients by increasing SARS-CoV-2 negative conversion rates and reducing recovery time. This traditional Chinese medicine shows significant improvements in clinical outcomes without severe adverse events.
Area of Science:
- Infectious Diseases
- Virology
- Traditional Chinese Medicine
Background:
- Effectiveness and safety of Huashibaidu granule (HSBD) for mild COVID-19 remain unclear.
- Evaluating HSBD in patients with mild Corona Virus Disease 2019 (COVID-19) is crucial.
Purpose of the Study:
- To assess the efficacy of HSBD in mild COVID-19 patients.
- To determine the impact of HSBD on SARS-CoV-2 negative conversion and clinical recovery.
Main Methods:
- Prospective, non-randomized controlled study involving 728 mild COVID-19 patients.
- Comparison between HSBD treatment (360 patients) and TCM placebo (368 patients) for 7 days.
- Primary endpoints: SARS-CoV-2 negative conversion rate and time; Secondary endpoints: hospitalization duration and clinical improvement.
Main Results:
- HSBD group showed a higher SARS-CoV-2 negative conversion rate (95.28% vs. 82.61%) at 7 days.
- HSBD significantly reduced negative conversion time by 2 days and hospitalization by 1 day.
- Clinical improvement rate was higher in the HSBD group (76.39% vs. 55.16%), with no severe adverse events.
Conclusions:
- HSBD is effective in treating mild COVID-19.
- HSBD accelerates SARS-CoV-2 clearance, shortens recovery time, and improves clinical condition.
- HSBD demonstrates a favorable safety profile in mild COVID-19 patients.
Background:
The effectiveness and safety of Huashibaidu granule (HSBD) in treating mild Corona Virus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 remain to be identified. We aimed to evaluate the effectiveness of HSBD in mild COVID-19 patients.
Methods:
A prospective, non-randomized, controlled study in mild COVID-19 patients was conducted in Shanghai, from April 8 to May 6, 2022. The enrolled patients were diagnosed as mild COVID-19. Finally, 360 patients received HSBD, and 368 patients received TCM placebo (administered orally 20 g twice daily for 7 days). The primary endpoints were the negative conversion rate of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the negative conversion time. Secondary endpoints included the hospitalized days and the improvement in the clinical condition.
Results:
The negative conversion rate of SARS-CoV-2 at 7 days posttreatment in the HSBD group was higher than that in the control group (95.28% vs. 82.61%, P < 0.001). The median negative conversion time in the HSBD group was markedly decreased by 2 days compared with the control group (3 [3-6] vs. 5 [4-7], P < 0.001). In addition, the median hospitalized day was shortened in the HSBD group by 1 day compared with the control group (6 [4-7] vs. 7 [5-9], P < 0.001). The clinical improvement rate (275/360 [76.39%]) in the HSBD group within 7 days was significantly higher than that (203/368 [55.16%]) in the control group (P < 0.001). The improvement of symptom scores in the HSBD group was higher than that in the control group (2 [1-4] vs. 1 [1-2], P < 0.001). No severe adverse events occurred.
Conclusions:
Our study suggested that HSBD effectively increased the negative conversion rate of SARS-CoV-2 and shortened the negative conversion time and hospitalized days in mild COVID-19 patients.
Clinical Trial Registration:
Chinese Clinical Trial Registry, ChiCTR2200058668.
More Related Videos
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023